CORD-19:2008f024274c53b0de1276f4047a6a641813fd98 / 405502-405600 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/CORD-19/sourceid/2008f024274c53b0de1276f4047a6a641813fd98","sourcedb":"CORD-19","sourceid":"2008f024274c53b0de1276f4047a6a641813fd98","text":"Maximal areas of compliance were noted in regards to pharmacologic treatments utilized (99%, 95%).","tracks":[{"project":"CORD-19-Sentences","denotations":[{"id":"T35100","span":{"begin":0,"end":98},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"attributes":[{"subj":"T35100","pred":"source","obj":"CORD-19-Sentences"}]},{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T442","span":{"begin":0,"end":98},"obj":"Sentence"}],"attributes":[{"subj":"T442","pred":"source","obj":"CORD-19_Custom_license_subset"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"CORD-19-Sentences","color":"#93c3ec","default":true},{"id":"CORD-19_Custom_license_subset","color":"#ddec93"}]}]}}